Anti-EGFR Recombinant Antibody (Nimotuzumab) (CAT#: TAB-710)
Recombinant humanized (from mouse) antibody expressed in CHO binding to human EGFR. Nimotuzumab is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck.
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.
Figure 1 EGFR signal transduction and effects of EGFR inhibition on downstream targets.
Scheme of EGFR signal transduction. Nimotuzumab and PD153035 are inhibitors of EGFR: Activation of EGFR results in activation of Akt signaling which relieves a TSC1/TSC2 as well as PRAS40 (via phosphorylation of Thr246)-mediated inhibition of mTORC1. RPS6 phosphorylation at Ser235/236 and Ser 240/244 is regulated by mTORC1.
Ronellenfitsch, M. W., Zeiner, P. S., Mittelbronn, M., Urban, H., Pietsch, T., Reuter, D., ... & Harter, P. N. (2018). Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma. Acta neuropathologica communications, 6(1), 81.
Figure 2 EGFR signal transduction and effects of EGFR inhibition on downstream targets.
LNT-229 cells were incubated in serum-free DMEM for 90 min with vehicle (DMSO control), PD153035 (dissolved in DMSO), control solution for nimotuzumab (placebo solution of the trial) or 1 ?M nimotuzumab as indicated. Cellular lysates were analyzed by immunoblot with antibodies as indicated.
Ronellenfitsch, M. W., Zeiner, P. S., Mittelbronn, M., Urban, H., Pietsch, T., Reuter, D., ... & Harter, P. N. (2018). Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma. Acta neuropathologica communications, 6(1), 81.
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Human
- Derivation
- Humanized (from mouse)
- Type
- IgG1 - kappa
- Species Reactivity
- Human
- Applications
- ELISA, IP, FC, FuncS, Neut, IF, IHC
- Trade name
- TheraCIM
- CAS
- 780758-10-3
- Generic Name
- nimotuzumab
- Biological Half-Life
- 62–304 hours
- ATC Code
- L01XC
- MW
- 147,659.45 g/mol
- Related Disease
- Glioma cancers
Product Property
- Purity
- >95.0%, determined by analysis by RP-HPLC & analysis by SDS-PAGE.
- Storage
- Store at -20°C. Avoid multiple freeze/thaw cycles.
Applications
- Application Notes
- The EGFR antibody has been reported in applications of Activ, WB.
Target
- Alternative Names
- nimotuzumab;TheraCIM;780758-10-3;hR3;h-R3;TheraCIM;BIOMAb EGFR;TheraCIM;Theraloc;CIMAher;EGFR;epidermal growth factor receptor;epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog) , ERBB;ERBB1;erythroblastic le
- Gene ID
- 1956
- UniProt ID
- P00533
Related Resources
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Nimotuzumab"
Afuco™ Anti-EGFR ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-710)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to human EGFR. It is a humanized monoclonal antibody.
DrugMonitor™ Anti-Nimotuzumab Antibody (VS-1224-YC808)Nimotuzumab (h-R3), a humanized monoclonal antibody targeting EGFR, has shown promising efficacy combined with radiation in several cancer types, meriting further investigation. The DrugMonitor™ Anti-Nimotuzumab Antibody (VS-1224-YC808) is an anti-drug antibody (ADA) against Nimotuzumab. This drug-based antibody is raised in mice immunized with the Nimotuzumab. The anti-Nimotuzumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Nimotuzumab in samples.
See other products for "EGFR"
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-H35 | Anti-Human EGFR Recombinant Antibody (Futuximab) | IF, WB, Inhib | IgG1 - kappa |
TAB-0225CL-F(E) | Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-0225CL-F(E)) | Block, Inhib, FuncS, Apop, In vivo | Chimeric (Mouse/Human) Fab |
TAB-272MZ-F(E) | Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-272MZ-F(E)) | FuncS | Chimeric (mouse/human) Fab |
TAB-308MZ-F(E) | Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-308MZ-F(E)) | ELISA, FC | Chimeric antibody (mouse/human) |
PABX-051-F (E) | Recombinant Mouse Anti-EGFR Antibody Fab Fragment (Matuzumab) | WB, Neut, FuncS | Fab |
Customer Reviews and Q&As
Reliable and Sturdy
Easy to Use
Affordable and Useful
Cite This Product
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-710, RRID: AB_3111988)
Popular products with customers
Application: WB, ELISA, FC, IP, FuncS, IF, Neut
Application: ELISA, IHC, FC, IP, IF, Inhib
Application: ELISA, Inhib, FuncS
Application: Neut, ELISA, IF, IP, FuncS, FC
Application: ELISA
Application: WB, ELISA, FuncS
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.